Stocks · Korea
0009K0
KOSDAQ
Aimed Bio
An overview for this page is not available in English yet. The figures below are updated daily.
Key figures 2026-10-07 basis
Returns and 52-week range
1W-27.40%
1M-43.25%
3M-48.34%
YTD-51.55%
52W high80,200원
52W low25,750원
From 52W high-66.96%
Financial results (consolidated)
| Period | Revenue | Operating income | Net income | OP margin |
|---|---|---|---|---|
| 2025 | 473억 | 208억 | 50억 | 43.9% |
| Quarterly | ||||
| 2025 3Q | 1억 | -59억 | -52억 | -5,135.6% |
| 2026 1Q | 85억 | -40억 | -20억 | -46.6% |
Company
Address: 서울특별시 송파구 정의로 67 9층, 10층, 11층(문정동, 엠케이타워)
Peers in the same sector
Recent filings
- 2026-05-15[기재정정]분기보고서 (2026.03)
- 2026-05-15분기보고서 (2026.03)
Source: DART (Financial Supervisory Service electronic disclosure)
Recent news
- 2026-08-21‘베링거 기술이전’ 에임드바이오 신약, 일본 임상 1상 승인 조선비즈
- 2026-08-12에임드바이오, 글로벌 기술이전 성과에…2분기 매출 166%↑ 서울경제
- 2026-07-22에임드바이오 “기술이전한 FGFR3 ADC, 임상 1상서 객관적 반응 ... 이데일리
- 2026-07-21에임드바이오 기술이전 신약, 임상 1상서 종양 감소 효과 확인 서울경제
Sources and notes
This page summarizes public filings, market data and news for information only. It is not a recommendation to buy or sell any security. Figures are as of the dates shown; check the original filings before making decisions.